Transgene . (NASDAQ:TRGNY)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Transgene . Charts. Click Here for more Transgene . Charts.](/p.php?pid=staticchart&s=N%5ETRGNY&p=8&t=15)
Merial and Transgene Sign a Collaboration Agreement to Develop
Products for Animal Health
STRASBOURG and LYON, France, June 15 /PRNewswire/ -- Transgene
(NASDAQ:TRGNY)(Nouveau Marche: FR0005175080) and Merial Limited today announced
a collaboration to develop products for animal health indications using
Transgene's vector platform. Under the terms of the agreement, Transgene will
provide Merial with research and development support regarding vector-based
expression of certain genes selected by Merial.
As part of the collaboration, Merial will conduct feasibility studies of
different recombinant viruses in veterinary target species, and will have the
right to execute an exclusive worldwide license for products originating from
the research process. The agreement provides for non-material payments to
Transgene during the research phase.
"We are very pleased to enter into this new collaboration with Merial, one of
the world's leading innovation-driven animal health companies," said
Jean-Francois Carmier, Chief Executive Officer of Transgene. "This agreement is
an opportunity to expand the applications of our vector platform in the field
of veterinary medicine".
"Merial is pleased to be working with Transgene in this important area," said
Kevin Schultz, Global Head of Merial Research and Development. "Our
collaboration with Transgene will expand Merial's ability to conduct research
on promising recombinant vectors, which play an important role in our R&D
strategy."
About Merial
Merial is a world leading innovation-driven animal health company, providing a
comprehensive range of products to enhance the health, well-being and
performance of a wide range of animals. Merial employs approximately 6,000
people and operates in more than 150 countries worldwide. Its 2003 sales were
in excess of $1.8 billion. Merial is a joint venture between Merck & Co., Inc.
and Aventis, S.A. For further information please see http://www.merial.com/ .
About Transgene
Transgene, based in Strasbourg, France, is a biopharmaceutical company
dedicated to the discovery and development of therapeutic vaccines,
immunotherapy products, and delivery technologies for the treatment of diseases
for which there is no cure or adequate treatment at present, with a focus on
the treatment of cancer. Transgene has five products in clinical development,
two of which are in Phase II clinical trials, two in Phase I/II and one that
has completed Phase I clinical trial. Transgene's proprietary vector technology
platform consists of adenovirus and poxvirus.
This press release contains forward-looking statements. Statements that are
not historical facts are based on Transgene's current expectations, beliefs,
estimates, forecasts and assumptions. Those statements are not guarantees of
future performance and involve certain risks, uncertainties and assumptions
which are difficult to predict. Accordingly, actual outcomes and results may
differ materially from what is expressed in those forward-looking statements.
Important factors that may affect Transgene's future operating results include
the following: Transgene's collaboration agreement with Merial Limited may not
provide Transgene with the anticipated benefits when expected, if at all;
Transgene's product candidates may not demonstrate therapeutic efficacy;
Transgene may be unable to obtain regulatory approval for its product
candidates; Transgene's patent rights may not provide it with any benefit and
the patents and licenses of others may prevent it from commercializing its
products; Transgene may be unable to conduct its clinical trials as quickly as
it has predicted; Transgene may not have sufficient resources to complete the
research and commercialization of any of its product candidates; competitors
may develop technologies or products superior to Transgene's technologies or
products; and other important factors described in Transgene's Annual Report on
Form 20-F for the year ended December 31, 2003 filed with the U.S. Securities
and Exchange Commission, including those factors described in the section
entitled "Risk Factors."
DATASOURCE: Merial Limited
CONTACT: Valerie Calenda, Director, Business Development, of Transgene,
+ (33) 3 88 27 91 43; or Michael Long of Cohn & Wolfe, +1-212-798-9775, for
Transgene; or Estelle Guillot-Tantay, + 33 (0) 1 53 70 74 93, or Laurence
Heilbronn, + 33 (0) 1 53 70 74 64, both of Image 7 for Transgene; or Margaret
May, Media Relations (Europe), +44 1279 77 5858, or ,
or Cindy Apgar, Media Relations (North America), +1-678-638-3690, or
, both of Merial Limited
Web site: http://www.merial.com/
http://www.transgene.fr/